JBT Marel Corporation (JBTM) Stock Price & How to Invest

JBT Marel Corporation (formerly John Bean Technologies) is a leading technology and equipment supplier to the food and beverage industry, operating in more than 30 countries. It sells processing, preparation, preservation, packaging, and automation systems across poultry, meat, fish, pet food, prepared foods, and beverages, and generates a meaningful and growing share of revenue from recurring aftermarket parts, service, and software. The company reorganized around two reportable segments, Protein Solutions and Prepared Food and Beverage Solutions, after closing its roughly $4.4 billion acquisition of Marel hf. in early 2025 and rebranding as JBT Marel.

The investment picture centers on scale and integration. The Marel deal roughly doubled the business, broadened its geographic and end-market reach, and set up cost-synergy targets of about $80 to $90 million in annualized run-rate savings, with about $60 million expected to land within 2026. Q1 2026 showed revenue up about 10 percent to ~$936 million with orders topping $1 billion. The second quarter, reported August 3, was mixed: revenue rose about 5 percent to ~$981 million (roughly 2 points from currency), orders were ~$1.03 billion for a 1.05x book-to-bill, backlog reached ~$1.54 billion, and adjusted EBITDA climbed to ~$168 million at a 17.1 percent margin. Protein Solutions grew 11 percent with a 24 percent segment margin, but Prepared Food and Beverage Solutions was flat with a weaker margin on logistics constraints and productivity issues, and adjusted EPS of ~$1.95 fell short of the ~$2.02 consensus. A $33 million non-cash impairment tied to a 2021 acquisition cut GAAP net income to ~$28 million. Management held full-year guidance of ~$3.99 to ~$4.065 billion of revenue and a 17 to 17.5 percent adjusted EBITDA margin, while pointing to a longer-term goal of 5 to 7 percent organic growth and a greater-than-20 percent EBITDA margin by 2028.

The market has grown more skeptical. The stock closed at ~$105.62 on October 16, 2026, down ~30% year to date, ~21% over one year and ~20% over three months, just above its 52-week low of ~$103.26 and far below the ~$170.19 high. At that price it trades near ~29 times trailing GAAP earnings but only ~11 times 2027 consensus EPS of ~$9.23, so results depend heavily on delivering the synergies and margin gains while continuing to pay down the debt taken on for the deal. Barclays initiated coverage at Overweight with a $150 target in September, and third-quarter results are due November 2, 2026, with consensus near ~$2.10 of adjusted EPS on ~$1.03 billion of revenue.

The business is cyclical and tied to capital-spending decisions by food processors, so orders can soften in a downturn. The Marel integration carries execution risk, and the June 2026 quarter showed it: logistics constraints and productivity inefficiencies weighed on Prepared Food and Beverage Solutions, adjusted EPS missed consensus, and a $33 million impairment on a 2021 acquisition hit GAAP results. Higher inflationary costs are being offset with pricing, which may not fully hold. Failing to realize the targeted synergies or margin expansion would pressure a stock that has already fallen about 30 percent in 2026 on doubts about exactly that. Debt taken on for the acquisition raises interest and refinancing sensitivity, and a large share of revenue is international, exposing results to foreign-exchange swings (currency added about 6 points to Q1 2026 growth and about 2 points to Q2). Short interest was reported near 9 percent of float in September, and end-market concentration in protein and reliance on continued equipment demand add further variability.

8 analysts publish price targets on JBTM, averaging $167.06 against a $104.24 price as of October 2026, or +60.3%. The published targets run from $118.00 to $210.00, a moderate spread, and the ratings split 7 buy, 0 hold, 1 sell. Over the last six months there have been 0 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full JBTM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on JBT Marel Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Marel merger integration and synergies. The 2025 Marel acquisition roughly doubled JBT's size and set annualized cost-synergy targets of about $80 to $90 million, with about $60 million of savings expected within 2026. The most optimistic published target, $210.00, assumes this works close to its best case.

The case against. The business is cyclical and tied to capital-spending decisions by food processors, so orders can soften in a downturn. The most pessimistic target, $118.00, is roughly what JBTM is worth if this bites instead.

Read the full bull and bear case on JBTM, including what would have to change to break either one. Walnut is not an investment adviser.

No. JBT Marel Corporation (JBTM) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see JBT Marel Corporation's investor relations page or your broker.

• Revenue (TTM): ~$3.93B; Q2 2026 ~$981M (+5% YoY)
• Adj. EBITDA margin (Q2 2026): ~17.1%; FY2026 guide 17.0% to 17.5%
• Net income (TTM): ~$193M, a ~4.9% net margin
• Adj. EPS (Q2 2026): ~$1.95 vs ~$2.02 expected
• P/E: ~29x trailing, ~11x forward
• Market cap: ~$5.5B at ~$105.62 (October 16, 2026)
• Net debt / adj. EBITDA: ~2.47x
• Dividend yield: ~0.4% ($0.40 annualized)

JBT Marel guided full-year 2026 revenue of roughly $3.99 to $4.065 billion with an adjusted EBITDA margin of about 17.0 to 17.5 percent. The trailing GAAP multiple of ~29 times is inflated by deal amortization, M&A costs and the Q2 impairment; on forward earnings the stock trades near ~11 times and about ~11 times EV to EBITDA, far below where it sat in mid-2026, which reflects the market's doubts about integration timing. The 8 analysts tracked by Yahoo Finance carry a mean target near ~$167, and Barclays started coverage in September at $150.

Other names that sit close to JBTM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get JBTM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so JBTM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where JBTM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

JBTM is a merger-integration story: a larger, more global food-processing equipment platform whose value depends on realizing Marel synergies and lifting margins toward its 2028 goals. After a ~30% slide in 2026 the market is pricing in doubt about that path, and the November 2 third-quarter report is the next data point.

Whether JBTM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is JBTM a buy or a sell?, and where the stock could go from here in the JBTM stock forecast.

For income investors, whether JBTM pays a dividend and how the payout looks is covered in does JBTM pay a dividend? And to weigh JBTM against a peer, read the full side-by-side comparisons: JBTM vs XE and JBTM vs GNRC.